

DAFTAR PUSTAKA

1. American Society of Health-System Pharmacists. AHFS Drug Information Essentials. McEvoy GK, editor. Bethesda, Maryland: American Society of Health-System Pharmacists; 2011.
2. Üner M, Yener G, Ergüven M. Design of colloidal drug carriers of celecoxib for use in treatment of breast cancer and leukemia. Mater Sci Eng C. 2019;103:1–11.
3. Fouad EA, El-Badry M, Mahrous GM, Alanazi FK, Neau SH, Alsarra IA. The use of spray-drying to enhance celecoxib solubility. Drug Dev Ind Pharm. 2011;37(12):1463–72.
4. The Ministry of Health Labour and Welfare. The Japanese Pharmacopoeia Drafts. Tokyo, Japan: the Ministry of Health, Labour and Welfare; 2019.
5. Seedher N, Bhatia S. Solubility enhancement of cox-2 inhibitors using various solvent systems. AAPS PharmSciTech. 2003;4(3):1–9.
6. Meng F, Ferreira R, Zhang F. Effect of surfactant level on properties of celecoxib amorphous solid dispersions. J Drug Deliv Sci Technol. 2019;49:301–7.
7. Cayman Chemical. Product Information: Celecoxib [Internet]. 2019. Available from: <https://www.caymanchem.com/product/10008672/celecoxib> (accessed on September 29, 2019)
8. Homayouni A, Sadeghi F, Nokhodchi A, Varshosaz J, Garekani HA. Preparation and characterization of celecoxib dispersions in Soluplus®: Comparison of spray drying and conventional methods. Iran J Pharm Res. 2015;14(1):35–50.
9. Savjani KT, Gajjar AK, Savjani JK. Drug Solubility: Importance and Enhancement Techniques. ISRN Pharm. 2012;1–10.
10. Subramanian N, Ray S, Ghosal SK, Bhadra R, Moulik SP. Formulation design of self-microemulsifying drug delivery systems for improved oral bioavailability of celecoxib. Biol Pharm Bull. 2004;27(12):1993–9.
11. Rawat S, Jain SK. Solubility enhancement of celecoxib using β -cyclodextrin inclusion complexes. Eur J Pharm Biopharm. 2004;57(2):263–7.
12. Dolenc A, Kristl J, Baumgartner S, Planinšek O. Advantages of celecoxib nanosuspension formulation and transformation into tablets. Int J Pharm. 2009;376(1–2):204–12.
13. Liu Y, Sun C, Hao Y, Jiang T, Zheng L, Wang S. Mechanism of dissolution enhancement and bioavailability of poorly water soluble celecoxib by preparing stable amorphous nanoparticles. J Pharm Pharm Sci. 2010;13(4):589–606.
14. Fudholi A. Disolusi dan Pelepasan Obat In-vitro. uji kekerasan, keregarasan, dan waktu hancur obat. Yogyakarta: Pustaka Pelajar; 2013.
15. Fong SYK, Ibisogly A, Bauer-Brandl A. Solubility enhancement of BCS

- Class II drug by solid phospholipid dispersions: Spray drying versus freeze-drying. *Int J Pharm.* 2015;496(2):382–91.
16. Pandya VM, Patel DJ, Patel JK, Patel RP. Formulation, characterization, and optimization of fast-dissolve tablets containing celecoxib solid dispersion. *Dissolution Technol.* 2009;16(4):22–7.
17. Xie T, Taylor LS. Dissolution performance of high drug loading celecoxib amorphous solid dispersions formulated with polymer combinations. *Pharm Res.* 2016;33(3):739–50.
18. Panda TK, Das D, Panigrahi L. Formulation development of solid dispersions of bosentan using Gelucire 50/13 and Poloxamer 188. *J Appl Pharm Sci.* 2016;6(9):027–33.
19. Rowe RCR, Sheskey PJS, Cook W. *Handbook Pharmaceutical Excipients*, Sixth Edition. 2009;1064.
20. Alhayali A, Tavellin S, Velaga S. Dissolution and precipitation behavior of ternary solid dispersions of ezetimibe in biorelevant media. *Drug Dev Ind Pharm.* 2017;43(1):79–88.
21. Dong W, Su X, Xu M, Hu M, Sun Y, Zhang P. Preparation, characterization, and in vitro/vivo evaluation of polymer-assisting formulation of atorvastatin calcium based on solid dispersion technique. *Asian J Pharm Sci.* 2018;13(6):546–54.
22. Ghareeb MM, Abdulrasool AA, Hussein AA, Noordin MI. Kneading technique for preparation of binary solid dispersion of meloxicam with Poloxamer 188. *AAPS PharmSciTech.* 2009;10(4):1206–15.
23. Fousteris E, Tarantili PA, Karavas E, Bikiaris D. Poly(vinyl pyrrolidone)-Poloxamer-188 solid dispersions prepared by hot melt extrusion: Thermal properties and release behavior. *J Therm Anal Calorim.* 2013;113(3):1037–47.
24. Haseley P, Oetjen G-W. *Freeze-Drying*. Third. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA Boschstr; 2018.
25. Franks F. *Freeze-drying of Pharmaceuticals and Biopharmaceuticals*. Cambridge, UK: The Royal Society of Chemistry Publishing; 2007.
26. Monisah R. Pembentukan dan Karakterisasi Dispersi Padat Asam Usnat-Gelucire 44/14 dengan Metode Freeze Drying. Universitas Andalas; 2018.
27. Noviza D, Fitriani L, Fauzi RZ. Dispersi padat asam usnat dengan teknik freeze drying menggunakan Poloxamer 188 sebagai polimer. *J Sains Farm Klin.* 2018;5(1):41–8.
28. Somer A, Roik JR, Ribeiro MA, Urban AM, Schoeffel A, Urban VM, et al. Nystatin complexation with β -cyclodextrin: Spectroscopic evaluation of inclusion by FT-Raman, photoacoustic spectroscopy, and ^1H NMR. *Mater Chem Phys.* 2020;239:1–5.
29. Khanfar M, Al-Taani B, Alsmadi M, Zayed A. Enhancement of the dissolution and bioavailability from freeze-dried powder of a hypcholesterolemic drug in the presence of Soluplus. *Powder Technol.* 2018;329:25–32.
30. Sweetman SC. *Martindale: The Complete Drug Reference*. Thirty-six. Journal of the Medical Library Association: JMLA. London, UK: Pharmaceutical Press; 2009. 3709 p.
31. PubChem. Celecoxib [Internet]. National Center for Biotechnology

- Information. PubChem Database. 2019. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/Celecoxib> (accessed on Sept. 29, 2019)
- 32. Günaydin S, Yilmaz A. Improvement of solubility of celecoxib by inclusion in MCM-41 mesoporous silica: Drug loading and release. *Turkish J Chem.* 2015;39(2):317–33.
 - 33. Andrews GP, Abu-Diak O, Kusmanto F, Hornsby P, Hui Z, Jones DS. Physicochemical characterization and drug-release properties of celecoxib hot-melt extruded glass solutions. *J Pharm Pharmacol.* 2010;62(11):1580–90.
 - 34. Medscape. Celebrex (celecoxib) dosing, indications, interactions, adverse effects, and more [Internet]. Medscape. 2018. Available from: <https://reference.medscape.com/drug/celebrex-celecoxib-343282#4> (accessed on Sept. 29, 2019)
 - 35. Homayouni A, Sadeghi F, Nokhodchi A, Varshosaz J, Afrasiabi Garekani H. Preparation and characterization of celecoxib solid dispersions; comparison of Poloxamer-188 and PVP-K30 as carriers. *Iran J Basic Med Sci.* 2014;17(5):322–31.
 - 36. Orringer EP, Ataga KI, Casella JF, Koshy M, Adams-Graves P, Luchtman-Jones L, et al. Purified Poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: A randomized controlled trial. *J Am Med Assoc.* 2001;286(17):2099–106.
 - 37. Serbest G, Horwitz J, Jost M, Barbee KA. Mechanisms of cell death and neuroprotection by Poloxamer 188 after mechanical trauma. *FASEB J.* 2006;20(2):308–10.
 - 38. Maskarinec SA, Hannig J, Lee RC, Lee KYC. Direct observation of Poloxamer 188 insertion into lipid monolayers. *Biophys J.* 2002;82(3):1453–9.
 - 39. Trianggani DF, Sulistiyaningsih. Artikel tinjauan: Dispersi padat. *Farmaka.* 2018;16(1):93–102.
 - 40. Patel BB, Patel JK, Chakraborty S, Shukla D. Revealing facts behind spray dried solid dispersion technology used for solubility enhancement. *Saudi Pharm J.* 2014;23(4):352–65.
 - 41. Kumar P, Singh C. A study on solubility enhancement methods for poorly water soluble drugs. *Am J Pharmacol Sci.* 2013;1(4):67–73.
 - 42. Janssens S, Van den Mooter G. Review: physical chemistry of solid dispersions. *J Pharm Pharmacol.* 2009;
 - 43. Kim KT, Lee JY, Lee MY, Song CK, Choi J, Kim D. Solid dispersions as a drug delivery system. *J Pharm Investig.* 2011;41(3):125–42.
 - 44. Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. *Drug Discov Today.* 2007;12(23/24):1068–75.
 - 45. Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems. *J Pharm Sci.* 1971;60(9):1281–302.
 - 46. Deshmane S V, Biyani KR. Characterization of solid dispersion: A review. *Adv Res Pharm Biol.* 2014;4(1):584–9.
 - 47. Sekiguchi K, Obi N. Studies on Absorption of Eutectic Mixture. I. A comparison of the behaviour of eutectic mixture of sulfathiazole and that of

- ordinary sulfathiazole in man. *Chem Pharm Bull.* 1961;9:866–72.
48. Mogal SA, Gurjar PN, Yamgar DS, Kamod AC. Solid dispersion technique for improving solubility of some poorly soluble drugs. *Der Pharm Lett.* 2012;4(5):1574–86.
49. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. *Eur J Pharm Biopharm.* 2000;50:47–60.
50. Ghosh PK, Sharma HK, Boruah N. Different methods used in solid dispersion. *IOSR J Pharm.* 2018;8(7):28–38.
51. Patil RM, Maniyar AH, Kale MT, Akarte AM, Baviskar DT. Solid dispersion: Strategy to enhance solubility. *Int J Pharm Sci Rev Res.* 2011;8(2):66–73.
52. Voigt R. Buku Pelajaran Teknologi Farmasi. Universitas Gajah Mada Press. Universitas Gajah Mada Press; 1994.
53. Day JG, Stacey GN. Cryopreservation and Freeze-Drying Protocols. Second. Totowa, New Jersey: Human Press; 2007.
54. Oetjen G-W, Haseley P. Freeze-Drying. Second. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA Boschstr; 2004.
55. Wang W, Chen M, Chen G. Issues in freeze drying of aqueous solutions. *Chinese J Chem Eng.* 2012;20(3):551–9.
56. Wang W. Lyophilization and development of solid protein pharmaceuticals. *Int J Pharm.* 2000;203(1–2):1–60.
57. Tang X, Pikal MJ. Design of freeze drying processes for pharmaceuticals: Practical advice. *Pharm Res.* 2004;21(2):191–200.
58. Dachriyanus. Analisis Struktur Senyawa Organik Secara Spektroskopi. Padang: Lembaga Pengembangan teknologi Informasi dan Komunikasi (LPTIK) Universitas Andalas; 2004.
59. Watson DG. Analisis Farmasi: Buku Ajar untuk Mahasiswa Farmasi dan Praktisi Kimia Farmasi. Edisi 2. Hadinata AH, editor. Elsevier. Penerbit Buku Kedokteran EGC; 2010.
60. Kementerian Kesehatan RI Direktorat Jendral Bina Kefarmasian dan Alat Kesehatan. Farmakope Indonesia Edisi V. Jakarta: Kementerian Kesehatan Republik Indonesia; 2014.
61. Permatasari D, Ramadhani S, Sopyan I, Muchtaridi. Ko-kristal: Teknik pembuatan ko-kristal. *Farmaka.* 2016;14(4):98–115.
62. Susanti S. Dispersi padat: Teknologi farmasi untuk meningkatkan kelarutan obat. *Farmaka.* 2016;4(3):1–15.
63. Martin A, Swarbrick J, Cammarata A. Farmasi Fisik: Dasar-Dasar Kimia Fisik dalam Ilmu Farmasetik. 3 Jilid 1. Yoshita, Baihaki IA, editors. Jakarta: Penerbit Univrsitas Indonesia (UI-Press); 1990.
64. Kementerian Kesehatan RI Direktorat Jendral Bina Kefarmasian dan Alat Kesehatan. Farmakope Indonesia Edisi III. Jakarta: Kementerian Kesehatan Republik Indonesia; 1979.
65. Khan S, Batchelor H, Hanson P, Perrie Y, Mohammed AR. Physicochemical characterisation , drug polymer dissolution and in vitro evaluation of phenacetin and phenylbutazone solid dispersions with polyethylene glycol 8000. *J Pharm Sci.* 2011;100(10):4281–94.
66. Agustin R, Lestari FI, Halim A. Pembentukan dan karakterisasi kompleks inklusi fenilbutazon dan b-siklodekstrin dengan metode co-grinding.

- Kartika J Ilm Farm. 2015;3(1):14–9.
- 67. Bhatt V, Shete G, Bansal AK. Mechanism of generation of drug nanocrystals in celecoxib: mannitol nanocrystalline solid dispersion. Int J Pharm. 2015;495(1):132–9.
 - 68. Verma U, Naik J, Mokale VJ. Preparation of freeze-dried solid dispersion powder using mannitol to enhance solubility of lovastatin and development of sustained release tablet dosage form. Am J Pharm Sci Nanotechnol. 2014;1(1):11–26.
 - 69. Wahyuningsih I, Fardiyannoor M, Yuwono T. Peningkatan kecepatan disolusi intrinsik piroksikam melalui pembentukan dispersi padat dengan polietilen glikol 6000. Media Farm. 2007;6(2):23–32.
 - 70. Zaini E, Witarsah AS, Agustin R. Enhancement of dissolution rate of meloxicam by co-grinding technique using hydroxypropyl methylcellulose. J Chem Pharm Res. 2014;6(11):263–7.

